Table 1.
Current clinical trials of CAR engineered immune cells, excluding conventional αβ T cells
| CAR immune cells | ClinicalTrials.gov identifier | Target | Disease | Starting material | CAR construct | Sponsor | Purpose |
|---|---|---|---|---|---|---|---|
| NK cells | NCT03692767 | CD22 | refractory B cell lymphoma | NA | NA | Allife Medical Science and Technology Co., Ltd. | to investigate the safety and efficacy of anti-CD22 CAR NK |
| NCT03690310 | CD19 | refractory B cell lymphoma | NA | NA | Allife Medical Science and Technology Co., Ltd. | to assess the safety and efficacy of anti-CD19 CAR NK | |
| NCT03692637 | Mesothelin | epithelial ovarian cancer | NA | NA | Allife Medical Science and Technology Co., Ltd. | to investigate the safety and efficacy of anti-mesothelin CAR NK | |
| NCT03692663 | PSMA | Castration-resistant prostate cancer | NA | NA | Allife Medical Science and Technology Co., Ltd. | to evaluate the safety and feasibility of anti-PSMA CAR NK cells | |
| NCT03824964 | CD19/CD22 | refractory B cell lymphoma | NA | NA | Allife Medical Science and Technology Co., Ltd. | to study on the safety and efficacy of anti-CD19/CD22 CAR NK cells | |
| NCT03940833 | BCMA | R/R multiple myeloma | NK-92 cells | NA | Asclepius Technology Company Group (Suzhou) Co., Ltd. | to assess the safety and feasibility followed by BCMA CAR-NK cells | |
| NCT03941457 | ROBO1 | pancreatic cancer | NK-92 cells | NA | Asclepius Technology Company Group (Suzhou) Co., Ltd. | to assess safety profile followed by administration of BiCAR-NK cells | |
| NCT03940820 | ROBO1 | solid tumor | NK-92 cells | NA | Asclepius Technology Company Group (Suzhou) Co., Ltd. | to assess the safety and effectiveness of ROBO1 CAR-NK cells to treat solid tumors | |
| NCT04324996 | viral S protein and host NKG2DL | COVID-19 | UCB cells | NA | Chongqing Public Health Medical Center | to assess the safety, tolerability, and efficacy of NKG2D-ACE2 CAR-NK cells | |
| NCT04245722 | CD19 | B cell lymphoma, CLL | iPS cells | CAR.19-NKG2D-2B4-CD3ζ-IL15RF-hnCD16 | Fate Therapeutics | to assess the incidence, nature and safety of FT596 (anti-CD19 CAR NK) monotherapy and with combination of anti-CD20 antibody | |
| NCT03383978 | HER2 | GBM | NK-92 cells | anti-HER2 NK-92/5.28.z | Johann Wolfgang Goethe University Hospital | to determine safety, tolerability and maximum tolerated dose (MTD) or maximum feasible dose (MFD) followed by NK-92/5.28z. | |
| NCT04847466 | PDL-1 | gastroesophageal junction (GEJ) cancers, advanced HNSCC | NK-92 cells | NA | National Cancer Institute (NCI) | to determine the clinical response rate (CR + PR) with irradiated PD-L1 CAR-NK cells in combination with N-803 plus pembrolizumab | |
| NCT01974479 | CD19 | B-ALL | NK cells | anti-CD19-BB-zeta | National University Health System, Singapore | to determine the minimal disease residual (MRD) monitoring followed by NK cell infusion | |
| NCT02944162 | CD33 | AML | NK-92 cells | anti-CD33,28,BB and zeta | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | to determine safety profile followed by administration of anti-CD33 CAR-NK cells | |
| NCT02742727 | CD7 | lymphoma, leukemia | NK-92 cells | anti-CD7,28,BB and zeta | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | to determine safety profile followed by administration of the anti-CD7 CAR-pNK cells | |
| NCT02839954 | MUC1 | solid tumor | NK-92 cells | anti-MUC1-pNK | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | to determine safety profile followed by administration of the anti-MUC1 CAR-pNK cells | |
| NCT02892695 | CD19 | lymphoma, leukemia | NK-92 cells | anti-CD19,28,BB and zeta | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | to determine the adverse events attributed to the administration of the anti-CD19 CAR-NK cells | |
| NCT04887012 | CD19 | B cell non-Hodgkin lymphoma | NK cells | NA | Second Affiliated Hospital, School of Medicine, Zhejiang University | to study the safety and effectiveness of HLA haploidentical CAR-NK cells | |
| NCT00995137 | CD19 | B-ALL | NK cells | anti-CD19-BB-zeta | St. Jude Children's Research Hospital | to determine the maximum tolerated dose of genetically modified NK cells | |
| NCT03415100 | NKG2DL | metastatic solid tumor | NK cells | NA | The Third Affiliated Hospital of Guangzhou Medical University | to determine the anti-tumor response followed by CAR-NK cell infusions | |
| NCT04796675 | CD19 | ALL CLL NHL |
CB cells | NA | Wuhan Union Hospital, China | to evaluate the primary safety and efficacy of CAR-NK-CD19 | |
| NCT04639739 | CD19 | NHL | NA | NA | Xinqiao Hospital of Chongqing | to assess safety and efficacy of anti-CD19 CAR NK | |
| NCT03656705 | NA | solid tumor | NK cells | NA | Xinxiang medical university | to evaluate the safety and feasibility of CAR-NK cell treatment | |
| NCT03056339 | CD19 | relapsed and refractory B lymphoid malignancies | UCB | CD19-CD28-zeta-2A-iCasp9-IL15 | M.D. Anderson Cancer Center | to assess the optimal dose, toxicity, and efficacy of CD19-CD28-zeta-2A-iCasp9-IL15 | |
| NKT cells | NCT03774654 | CD19 | refractory B cell lymphoma, relapsed adult ALL relapsed CLL, relapsed non-Hodgkin lymphoma |
NKT cells | NA | Baylor College of Medicine | to determine the dose limiting toxicity (DLT) rate |
| NCT04814004 | CD19 | relapsed, refractory, or high-risk B cell malignancies | iNKT | hCD19.IL15.CAR-iNKT | Kai Lin Xu; Jun Nian Zheng and Xuzhou Medical University | to evaluate the safety and feasibility of IL-15-expressing anti-CD19 CAR iNKT (hCD19.IL15.CAR-iNKT) cells | |
| NCT03294954 | GD2 | neuroblastoma | NKT cells | CAR.GD2-CD28-CD3ζ-IL15 | Baylor College of Medicine | to determine the maximum tolerated dose (mTD) | |
| CAR γδ T cells | NCT04702841 | CD7 | T-ALL | γδ T cells | NA | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | to evaluate the efficacy of CAR - γδ T cells |
| NCT04107142 | NKG2DL | colorectal cancer, triple-negative breast cancer, sarcoma, nasopharyngeal carcinoma, prostate cancer, gastric cancer | γδ T cells | NA | CytoMed Therapeutics Pte Ltd | to evaluate the safety of CTM-N2D and the feasibility to produce CTM-N2D for three target dose levels | |
| NCT04735471 | CD20 | B cell malignancies | γδ T cells | NA | Adicet Bio, Inc | to assess the safety and efficacy study of ADI-001 anti-CD20 CAR-engineered allogeneic gamma delta T cells in adults with B cell malignancies, in monotherapy and combination with IL-2 | |
| CAR Tregs | NCT04817774 | HLA-A2 | kidney transplantation | Treg cells | NA | Sangamo Therapeutics | safety and tolerability of TX200-TR101 |
| CAR macrophages | NCT04660929 | HER2 | HER2-positive carcinoma | macrophages | NA | Carisma Therapeutics Inc | assess the safety and tolerability of CT-0508 and to assess the feasibility of manufacturing CT-0508 |
| CAR CIK cells | NCT03389035 | CD19 | B-ALL | CIK cells | CAR.19-CD28-OX40- CD3ζ | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | feasibility and safety of a single dose of transposon-manipulated allogeneic CARCIK-CD19 |
| iPSC-derived CAR T cells | NCT04629729 | CD19 | B cell lymphoma, CLL, B cell ALL | iPS cells | NA | Fate Therapeutics | to assess the incidence, nature, and safety of FT819 (truncated TCR anti-CD19 CAR T) monotherapy and with combination with IL-2 |